NEW YORK ( TheStreet) -- Tuesday night will mark the 2,000th episode of Jim Cramer's "Mad Money" TV program on CNBC. Together with Nicole Urken, the program's research director, Cramer talks about the show and some of the picks.

Cramer said that the one-man show wasn't one that seemed like it would last, but it proved to be helpful and accessible to individual investors.

Although some will argue that picking individual stocks is not the way to go for the average individual investor, Cramer has long urged investors to build wealth by selecting quality names with growth.

One example is Regeneron Pharmaceuticals ( REGN), a stock that Cramer got behind when it was trading at $5. He said it was a buy after speaking with the CEO about its different types of drug treatments.

The stock is now changing hands for more than $300.

Netflix ( NFLX) and Priceline.com ( PCLN) were two others that were mentioned early on and are responsible for some handsome gains.

Cramer said that although not all of his picks are winners, he tries to break down complex unknowns into understandable explanations for the retail investor.

He concluded that the winning recipe for stock picking is to isolate the stocks that work and perform well, and then apply that method to other stocks.

-- Written by Bret Kenwell in Petoskey, Mich.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, has no positions in the stocks mentioned.
Bret Kenwell currently writes, blogs and also contributes to Robert Weinstein's Weekly Options Newsletter. Focuses on short-to-intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round